Spectre Acquisition Corp

Spectre Acquisition Corp exemplifies a standard SPAC structure with $60M IPO (6M units at $10), sponsor funding $2.3M private units, placing 100% proceeds in trust for non-PRC targets. The 18-month deadline (extendable to 21 months for $0.033/share) pressures execution amid high redemption risks—public holders can redeem at ~$10/share regardless of vote, capped at 15% per group. Sponsor holds 22.38% via $25K founder shares (anti-dilution locks 20% minimum), creating immediate 99.6% dilution to public at IPO and incentivizing completion even at suboptimal terms, as sponsor profits above $0.017/share breakeven.

Financials show pre-IPO losses of $50K with $194K working capital deficit, funded by sponsor's $600K note. No revenue, pure SPAC burn. Use of $800K outside trust covers search costs, admin ($10K/month to sponsor), D&O insurance. ARC Securities underwrites with 1.5% cash + 1% deferred fee, plus sponsor's $200K to ARC affiliate for advisory—minimal dilution claimed.

Key differentiator: Explicit PRC exclusion despite sponsor/CEO (Jingxia Hua, China resident) and leadership's China ties, citing CFIUS risks, regulatory oversight, HFCAA/PCAOB issues (auditor Guangdong Prouden CPAs GP, China-based but PCAOB-accessible). This narrows pool but mitigates U.S. national security blocks. Conflicts abound: Management splits time across entities, sponsor consent needed for deals, no fairness opinions unless affiliated/board deems necessary.

Investor implications: High redemption flexibility favors exits but risks deal failure if cash drops below targets' minimums. Sponsor alignment via promote ensures motivation but dilutes public. Nasdaq listing (SPEXU/SPEX/SPEXW) post-separation; warrants ($11.50 strike, redeemable >$18) add optionality. Cayman incorporation limits U.S. judgment enforcement. Overall, classic SPAC bet on management sourcing non-China deal amid regulatory scrutiny.